ARCA biopharma Announces Proposed Public Offering Of Common Stock And Warrants
2/4/2014 9:26:37 AM
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it intends to offer and sell common stock and warrants in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares and warrants are being offered under the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC) and declared effective on April 4, 2011 (Registration No. 333-172686). The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital and operational purposes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by